Serum modified HDL was associated with cardiovascular disease in a Japanese community-based cohort
Abstract Background Previous studies have shown that high density lipoprotein (HDL) is protective against cardiovascular disease (CVD). However, recent studies suggested that function of HDL was more important than HDL cholesterol levels. The present study aimed to clarify the relationship between m...
Gespeichert in:
Veröffentlicht in: | European journal of public health 2019-11, Vol.29 (Supplement_4) |
---|---|
Hauptverfasser: | , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext bestellen |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | |
---|---|
container_issue | Supplement_4 |
container_start_page | |
container_title | European journal of public health |
container_volume | 29 |
creator | Okamura, T Sata, M Iida, M Kakino, A Harada, S Hirata, A Usami, Y Sugiyama, D Sawamura, T Takabayashi, T |
description | Abstract
Background
Previous studies have shown that high density lipoprotein (HDL) is protective against cardiovascular disease (CVD). However, recent studies suggested that function of HDL was more important than HDL cholesterol levels. The present study aimed to clarify the relationship between modified HDL levels and CVD incidence.
Methods
LOX-1 (lectin-like oxidized LDL receptor) is the receptor that mediates modified LDL (low density lipoprotein) activity; however, some lipoproteins with apolipoprotein A1 (Apo A-1) are also bonded to LOX-1. In this study, serum LOX-1 ligand containing Apo A-1 was defined as modified HDL, which were measured by our new development method. We conducted a nested case-control study in a Japanese cohort study, involving 11,002 community dwellers. During 4.0 years follow-up, we observed 127 new CVD onsets. For each CVD case, age and sex matched three controls were randomly selected (N = 381). Serum samples collected at baseline survey stored at − 80 °C were used for the measurement of modified HDL. We estimated multivariable-adjusted odds ratio (OR) and 95% confidence interval (CI) for the association between modified HDL levels and CVD by conditional logistic regression.
Results
Modified HDL levels were associated with increased risk of CVD (OR for one unit increase of log transformed modified HDL, 2.05: 95% CI, 1.16-3.62) after adjustment for body mass index, hypertension, diabetes, LDL cholesterol, HDL cholesterol, lipid lowering agents, chronic kidney disease, smoking and alcohol drinking. The magnitude of OR was almost equivalent to those of hypertension and diabetes, which were 2.33 (95% CI, 1.37-3.98) and 2.61 (95% CI, 1.48-4.59), respectively. On the other hands, other lipids markers showed relatively weak associations with CVD.
Conclusions
Serum modified HDL, i.e., LOX-1 ligand containing Apo A-1, might be a novel predictive marker for CVD in apparently healthy individuals.
Key messages
Recent epidemiologic studies suggested that function of high-density lipoprotein (HDL) was more important than HDL cholesterol level itself to predict cardiovascular disease.
Modified HDL measured by a novel cell-free, non-fluorescent method as LOX-1 ligand containing Apo A-1, was a predictive marker for CVD after adjusting for other traditional risk factors. |
doi_str_mv | 10.1093/eurpub/ckz187.170 |
format | Article |
fullrecord | <record><control><sourceid>proquest_TOX</sourceid><recordid>TN_cdi_proquest_journals_2430181123</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><oup_id>10.1093/eurpub/ckz187.170</oup_id><sourcerecordid>2430181123</sourcerecordid><originalsourceid>FETCH-LOGICAL-c1500-56f2fd74e12b26dd43c4b3d1159ec16722b236b04ffcaa0d61dc0b67614812093</originalsourceid><addsrcrecordid>eNqNkE1OwzAQhS0EEqVwAHaW2JLW4zhOukTlp6BKLACJneXYjurSxMGOqcrpMQoHYDUzb96bkT6ELoHMgCzyuYm-j_VcfXxDVc6gJEdoAoyzLOfk_Tj1QCADyukpOgthSwgpyopOUP1ifGxx67RtrNF4dbvGexmwDMEpK4ck7e2wwUp6bd2XDCrupMfaBiODwbbDEj_JXnYmTcq1bezscMjqtNRp3jg_nKOTRu6CufirU_R2f_e6XGXr54fH5c06U1AQkhW8oY0umQFaU641yxWrcw1QLIwCXtIk57wmrGmUlERz0IrUvOTAKqCJwRRdjXd77z6jCYPYuui79FJQlhOoAGieXDC6lHcheNOI3ttW-oMAIn5RihGlGFGKhDJlrseMi_0_7D-B7nj8</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2430181123</pqid></control><display><type>article</type><title>Serum modified HDL was associated with cardiovascular disease in a Japanese community-based cohort</title><source>Access via Oxford University Press (Open Access Collection)</source><creator>Okamura, T ; Sata, M ; Iida, M ; Kakino, A ; Harada, S ; Hirata, A ; Usami, Y ; Sugiyama, D ; Sawamura, T ; Takabayashi, T</creator><creatorcontrib>Okamura, T ; Sata, M ; Iida, M ; Kakino, A ; Harada, S ; Hirata, A ; Usami, Y ; Sugiyama, D ; Sawamura, T ; Takabayashi, T</creatorcontrib><description>Abstract
Background
Previous studies have shown that high density lipoprotein (HDL) is protective against cardiovascular disease (CVD). However, recent studies suggested that function of HDL was more important than HDL cholesterol levels. The present study aimed to clarify the relationship between modified HDL levels and CVD incidence.
Methods
LOX-1 (lectin-like oxidized LDL receptor) is the receptor that mediates modified LDL (low density lipoprotein) activity; however, some lipoproteins with apolipoprotein A1 (Apo A-1) are also bonded to LOX-1. In this study, serum LOX-1 ligand containing Apo A-1 was defined as modified HDL, which were measured by our new development method. We conducted a nested case-control study in a Japanese cohort study, involving 11,002 community dwellers. During 4.0 years follow-up, we observed 127 new CVD onsets. For each CVD case, age and sex matched three controls were randomly selected (N = 381). Serum samples collected at baseline survey stored at − 80 °C were used for the measurement of modified HDL. We estimated multivariable-adjusted odds ratio (OR) and 95% confidence interval (CI) for the association between modified HDL levels and CVD by conditional logistic regression.
Results
Modified HDL levels were associated with increased risk of CVD (OR for one unit increase of log transformed modified HDL, 2.05: 95% CI, 1.16-3.62) after adjustment for body mass index, hypertension, diabetes, LDL cholesterol, HDL cholesterol, lipid lowering agents, chronic kidney disease, smoking and alcohol drinking. The magnitude of OR was almost equivalent to those of hypertension and diabetes, which were 2.33 (95% CI, 1.37-3.98) and 2.61 (95% CI, 1.48-4.59), respectively. On the other hands, other lipids markers showed relatively weak associations with CVD.
Conclusions
Serum modified HDL, i.e., LOX-1 ligand containing Apo A-1, might be a novel predictive marker for CVD in apparently healthy individuals.
Key messages
Recent epidemiologic studies suggested that function of high-density lipoprotein (HDL) was more important than HDL cholesterol level itself to predict cardiovascular disease.
Modified HDL measured by a novel cell-free, non-fluorescent method as LOX-1 ligand containing Apo A-1, was a predictive marker for CVD after adjusting for other traditional risk factors.</description><identifier>ISSN: 1101-1262</identifier><identifier>EISSN: 1464-360X</identifier><identifier>DOI: 10.1093/eurpub/ckz187.170</identifier><language>eng</language><publisher>Oxford: Oxford University Press</publisher><subject>Alcohol ; Body mass index ; Body size ; Cardiovascular disease ; Cardiovascular diseases ; Cholesterol ; Community involvement ; Confidence intervals ; Density ; Diabetes ; Diabetes mellitus ; Disease ; Drinking behavior ; Epidemiology ; Fluorescence ; Heart diseases ; High density lipoprotein ; Hypertension ; Kidney diseases ; Ligands ; Lipids ; Lipoproteins ; Liquid oxygen ; Low density lipoprotein ; LOX-1 protein ; Markers ; Public health ; Receptors ; Risk analysis ; Risk factors ; Smoking ; Statistical analysis</subject><ispartof>European journal of public health, 2019-11, Vol.29 (Supplement_4)</ispartof><rights>The Author(s) 2019. Published by Oxford University Press on behalf of the European Public Health Association. All rights reserved. 2019</rights><rights>The Author(s) 2019. Published by Oxford University Press on behalf of the European Public Health Association. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>315,782,786,1586,1606,27873,27931,27932</link.rule.ids><linktorsrc>$$Uhttps://dx.doi.org/10.1093/eurpub/ckz187.170$$EView_record_in_Oxford_University_Press$$FView_record_in_$$GOxford_University_Press</linktorsrc></links><search><creatorcontrib>Okamura, T</creatorcontrib><creatorcontrib>Sata, M</creatorcontrib><creatorcontrib>Iida, M</creatorcontrib><creatorcontrib>Kakino, A</creatorcontrib><creatorcontrib>Harada, S</creatorcontrib><creatorcontrib>Hirata, A</creatorcontrib><creatorcontrib>Usami, Y</creatorcontrib><creatorcontrib>Sugiyama, D</creatorcontrib><creatorcontrib>Sawamura, T</creatorcontrib><creatorcontrib>Takabayashi, T</creatorcontrib><title>Serum modified HDL was associated with cardiovascular disease in a Japanese community-based cohort</title><title>European journal of public health</title><description>Abstract
Background
Previous studies have shown that high density lipoprotein (HDL) is protective against cardiovascular disease (CVD). However, recent studies suggested that function of HDL was more important than HDL cholesterol levels. The present study aimed to clarify the relationship between modified HDL levels and CVD incidence.
Methods
LOX-1 (lectin-like oxidized LDL receptor) is the receptor that mediates modified LDL (low density lipoprotein) activity; however, some lipoproteins with apolipoprotein A1 (Apo A-1) are also bonded to LOX-1. In this study, serum LOX-1 ligand containing Apo A-1 was defined as modified HDL, which were measured by our new development method. We conducted a nested case-control study in a Japanese cohort study, involving 11,002 community dwellers. During 4.0 years follow-up, we observed 127 new CVD onsets. For each CVD case, age and sex matched three controls were randomly selected (N = 381). Serum samples collected at baseline survey stored at − 80 °C were used for the measurement of modified HDL. We estimated multivariable-adjusted odds ratio (OR) and 95% confidence interval (CI) for the association between modified HDL levels and CVD by conditional logistic regression.
Results
Modified HDL levels were associated with increased risk of CVD (OR for one unit increase of log transformed modified HDL, 2.05: 95% CI, 1.16-3.62) after adjustment for body mass index, hypertension, diabetes, LDL cholesterol, HDL cholesterol, lipid lowering agents, chronic kidney disease, smoking and alcohol drinking. The magnitude of OR was almost equivalent to those of hypertension and diabetes, which were 2.33 (95% CI, 1.37-3.98) and 2.61 (95% CI, 1.48-4.59), respectively. On the other hands, other lipids markers showed relatively weak associations with CVD.
Conclusions
Serum modified HDL, i.e., LOX-1 ligand containing Apo A-1, might be a novel predictive marker for CVD in apparently healthy individuals.
Key messages
Recent epidemiologic studies suggested that function of high-density lipoprotein (HDL) was more important than HDL cholesterol level itself to predict cardiovascular disease.
Modified HDL measured by a novel cell-free, non-fluorescent method as LOX-1 ligand containing Apo A-1, was a predictive marker for CVD after adjusting for other traditional risk factors.</description><subject>Alcohol</subject><subject>Body mass index</subject><subject>Body size</subject><subject>Cardiovascular disease</subject><subject>Cardiovascular diseases</subject><subject>Cholesterol</subject><subject>Community involvement</subject><subject>Confidence intervals</subject><subject>Density</subject><subject>Diabetes</subject><subject>Diabetes mellitus</subject><subject>Disease</subject><subject>Drinking behavior</subject><subject>Epidemiology</subject><subject>Fluorescence</subject><subject>Heart diseases</subject><subject>High density lipoprotein</subject><subject>Hypertension</subject><subject>Kidney diseases</subject><subject>Ligands</subject><subject>Lipids</subject><subject>Lipoproteins</subject><subject>Liquid oxygen</subject><subject>Low density lipoprotein</subject><subject>LOX-1 protein</subject><subject>Markers</subject><subject>Public health</subject><subject>Receptors</subject><subject>Risk analysis</subject><subject>Risk factors</subject><subject>Smoking</subject><subject>Statistical analysis</subject><issn>1101-1262</issn><issn>1464-360X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>7TQ</sourceid><recordid>eNqNkE1OwzAQhS0EEqVwAHaW2JLW4zhOukTlp6BKLACJneXYjurSxMGOqcrpMQoHYDUzb96bkT6ELoHMgCzyuYm-j_VcfXxDVc6gJEdoAoyzLOfk_Tj1QCADyukpOgthSwgpyopOUP1ifGxx67RtrNF4dbvGexmwDMEpK4ck7e2wwUp6bd2XDCrupMfaBiODwbbDEj_JXnYmTcq1bezscMjqtNRp3jg_nKOTRu6CufirU_R2f_e6XGXr54fH5c06U1AQkhW8oY0umQFaU641yxWrcw1QLIwCXtIk57wmrGmUlERz0IrUvOTAKqCJwRRdjXd77z6jCYPYuui79FJQlhOoAGieXDC6lHcheNOI3ttW-oMAIn5RihGlGFGKhDJlrseMi_0_7D-B7nj8</recordid><startdate>20191101</startdate><enddate>20191101</enddate><creator>Okamura, T</creator><creator>Sata, M</creator><creator>Iida, M</creator><creator>Kakino, A</creator><creator>Harada, S</creator><creator>Hirata, A</creator><creator>Usami, Y</creator><creator>Sugiyama, D</creator><creator>Sawamura, T</creator><creator>Takabayashi, T</creator><general>Oxford University Press</general><general>Oxford Publishing Limited (England)</general><scope>AAYXX</scope><scope>CITATION</scope><scope>7T2</scope><scope>7TQ</scope><scope>C1K</scope><scope>DHY</scope><scope>DON</scope><scope>K9.</scope><scope>NAPCQ</scope></search><sort><creationdate>20191101</creationdate><title>Serum modified HDL was associated with cardiovascular disease in a Japanese community-based cohort</title><author>Okamura, T ; Sata, M ; Iida, M ; Kakino, A ; Harada, S ; Hirata, A ; Usami, Y ; Sugiyama, D ; Sawamura, T ; Takabayashi, T</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c1500-56f2fd74e12b26dd43c4b3d1159ec16722b236b04ffcaa0d61dc0b67614812093</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Alcohol</topic><topic>Body mass index</topic><topic>Body size</topic><topic>Cardiovascular disease</topic><topic>Cardiovascular diseases</topic><topic>Cholesterol</topic><topic>Community involvement</topic><topic>Confidence intervals</topic><topic>Density</topic><topic>Diabetes</topic><topic>Diabetes mellitus</topic><topic>Disease</topic><topic>Drinking behavior</topic><topic>Epidemiology</topic><topic>Fluorescence</topic><topic>Heart diseases</topic><topic>High density lipoprotein</topic><topic>Hypertension</topic><topic>Kidney diseases</topic><topic>Ligands</topic><topic>Lipids</topic><topic>Lipoproteins</topic><topic>Liquid oxygen</topic><topic>Low density lipoprotein</topic><topic>LOX-1 protein</topic><topic>Markers</topic><topic>Public health</topic><topic>Receptors</topic><topic>Risk analysis</topic><topic>Risk factors</topic><topic>Smoking</topic><topic>Statistical analysis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Okamura, T</creatorcontrib><creatorcontrib>Sata, M</creatorcontrib><creatorcontrib>Iida, M</creatorcontrib><creatorcontrib>Kakino, A</creatorcontrib><creatorcontrib>Harada, S</creatorcontrib><creatorcontrib>Hirata, A</creatorcontrib><creatorcontrib>Usami, Y</creatorcontrib><creatorcontrib>Sugiyama, D</creatorcontrib><creatorcontrib>Sawamura, T</creatorcontrib><creatorcontrib>Takabayashi, T</creatorcontrib><collection>CrossRef</collection><collection>Health and Safety Science Abstracts (Full archive)</collection><collection>PAIS Index</collection><collection>Environmental Sciences and Pollution Management</collection><collection>PAIS International</collection><collection>PAIS International (Ovid)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><jtitle>European journal of public health</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>Okamura, T</au><au>Sata, M</au><au>Iida, M</au><au>Kakino, A</au><au>Harada, S</au><au>Hirata, A</au><au>Usami, Y</au><au>Sugiyama, D</au><au>Sawamura, T</au><au>Takabayashi, T</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Serum modified HDL was associated with cardiovascular disease in a Japanese community-based cohort</atitle><jtitle>European journal of public health</jtitle><date>2019-11-01</date><risdate>2019</risdate><volume>29</volume><issue>Supplement_4</issue><issn>1101-1262</issn><eissn>1464-360X</eissn><abstract>Abstract
Background
Previous studies have shown that high density lipoprotein (HDL) is protective against cardiovascular disease (CVD). However, recent studies suggested that function of HDL was more important than HDL cholesterol levels. The present study aimed to clarify the relationship between modified HDL levels and CVD incidence.
Methods
LOX-1 (lectin-like oxidized LDL receptor) is the receptor that mediates modified LDL (low density lipoprotein) activity; however, some lipoproteins with apolipoprotein A1 (Apo A-1) are also bonded to LOX-1. In this study, serum LOX-1 ligand containing Apo A-1 was defined as modified HDL, which were measured by our new development method. We conducted a nested case-control study in a Japanese cohort study, involving 11,002 community dwellers. During 4.0 years follow-up, we observed 127 new CVD onsets. For each CVD case, age and sex matched three controls were randomly selected (N = 381). Serum samples collected at baseline survey stored at − 80 °C were used for the measurement of modified HDL. We estimated multivariable-adjusted odds ratio (OR) and 95% confidence interval (CI) for the association between modified HDL levels and CVD by conditional logistic regression.
Results
Modified HDL levels were associated with increased risk of CVD (OR for one unit increase of log transformed modified HDL, 2.05: 95% CI, 1.16-3.62) after adjustment for body mass index, hypertension, diabetes, LDL cholesterol, HDL cholesterol, lipid lowering agents, chronic kidney disease, smoking and alcohol drinking. The magnitude of OR was almost equivalent to those of hypertension and diabetes, which were 2.33 (95% CI, 1.37-3.98) and 2.61 (95% CI, 1.48-4.59), respectively. On the other hands, other lipids markers showed relatively weak associations with CVD.
Conclusions
Serum modified HDL, i.e., LOX-1 ligand containing Apo A-1, might be a novel predictive marker for CVD in apparently healthy individuals.
Key messages
Recent epidemiologic studies suggested that function of high-density lipoprotein (HDL) was more important than HDL cholesterol level itself to predict cardiovascular disease.
Modified HDL measured by a novel cell-free, non-fluorescent method as LOX-1 ligand containing Apo A-1, was a predictive marker for CVD after adjusting for other traditional risk factors.</abstract><cop>Oxford</cop><pub>Oxford University Press</pub><doi>10.1093/eurpub/ckz187.170</doi><oa>free_for_read</oa></addata></record> |
fulltext | fulltext_linktorsrc |
identifier | ISSN: 1101-1262 |
ispartof | European journal of public health, 2019-11, Vol.29 (Supplement_4) |
issn | 1101-1262 1464-360X |
language | eng |
recordid | cdi_proquest_journals_2430181123 |
source | Access via Oxford University Press (Open Access Collection) |
subjects | Alcohol Body mass index Body size Cardiovascular disease Cardiovascular diseases Cholesterol Community involvement Confidence intervals Density Diabetes Diabetes mellitus Disease Drinking behavior Epidemiology Fluorescence Heart diseases High density lipoprotein Hypertension Kidney diseases Ligands Lipids Lipoproteins Liquid oxygen Low density lipoprotein LOX-1 protein Markers Public health Receptors Risk analysis Risk factors Smoking Statistical analysis |
title | Serum modified HDL was associated with cardiovascular disease in a Japanese community-based cohort |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-03T23%3A39%3A49IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_TOX&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Serum%20modified%20HDL%20was%20associated%20with%20cardiovascular%20disease%20in%20a%20Japanese%20community-based%20cohort&rft.jtitle=European%20journal%20of%20public%20health&rft.au=Okamura,%20T&rft.date=2019-11-01&rft.volume=29&rft.issue=Supplement_4&rft.issn=1101-1262&rft.eissn=1464-360X&rft_id=info:doi/10.1093/eurpub/ckz187.170&rft_dat=%3Cproquest_TOX%3E2430181123%3C/proquest_TOX%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2430181123&rft_id=info:pmid/&rft_oup_id=10.1093/eurpub/ckz187.170&rfr_iscdi=true |